Silke Reinartz Selected Research

abagovomab

1/2010	Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.
9/2006	Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
3/2004	Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).
6/2003	Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silke Reinartz Research Topics

Disease

16	Neoplasms (Cancer) 01/2020 - 06/2003
13	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 06/2003
9	Carcinoma (Carcinomatosis) 01/2022 - 03/2004
9	Ascites 01/2020 - 01/2014
4	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 09/2018
1	Adenocarcinoma 09/2018
1	Chronic Pancreatitis 09/2018
1	Disease Progression 01/2016
1	Carcinogenesis 07/2012
1	Breast Neoplasms (Breast Cancer) 04/2009

Drug/Important Bio-Agent (IBA)

4	LipidsIBA 01/2022 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2016
4	Interleukin-6 (Interleukin 6)IBA 01/2019 - 06/2003
4	VaccinesIBA 01/2010 - 06/2003
4	abagovomabIBA 01/2010 - 06/2003
3	CytokinesIBA 01/2019 - 01/2014
3	Interleukin-10 (Interleukin 10)IBA 01/2018 - 01/2014
3	AntigensIBA 07/2012 - 06/2003
2	Arachidonic Acid (Vitamin F)IBA 01/2022 - 01/2021
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021 - 05/2015
2	Small Interfering RNA (siRNA)IBA 01/2020 - 07/2012
2	Conditioned Culture MediaIBA 01/2020 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 09/2018 - 01/2018
2	Interleukin-12 (IL 12)IBA 01/2018 - 01/2017
2	LigandsIBA 01/2017 - 05/2015
2	Monoclonal AntibodiesIBA 09/2006 - 06/2003
1	Fibronectins (Fibronectin)IBA 01/2020
1	Calbindin 2IBA 01/2020
1	Collagen Type I (Type I Collagen)IBA 01/2020
1	TenascinIBA 01/2020
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2019
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2019
1	P-2 (P 2)IBA 01/2019
1	Lysophosphatidic Acid ReceptorsIBA 01/2019
1	Secretory Phospholipases A2IBA 01/2019
1	lysophosphatidic acidIBA 01/2019
1	GlypicansIBA 09/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	ChromatinIBA 01/2018
1	Chemokine CXCL9IBA 01/2018
1	NK Cell Lectin-Like Receptor Subfamily KIBA 01/2017
1	Biological ProductsIBA 01/2017
1	InterferonsIBA 01/2017
1	Frizzled ReceptorsIBA 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 05/2015
1	Linoleic Acid (Linoleate)IBA 05/2015
1	CA-125 Antigen (CA 125 Antigen)IBA 07/2012
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2009
1	LY 117018IBA 04/2009
1	Raloxifene Hydrochloride (Evista)FDA Link 04/2009
1	Estrogen ReceptorsIBA 04/2009
1	Celecoxib (Celebrex)FDA Link 04/2009
1	Selective Estrogen Receptor Modulators (SERM)IBA 04/2009
1	Anti-Idiotypic AntibodiesIBA 06/2005
1	Neoplasm Antigens (Tumor Antigens)IBA 03/2004
1	AntibodiesIBA 03/2004
1	CarbohydratesIBA 06/2003

Therapy/Procedure

3	Therapeutics 01/2018 - 01/2017
1	Drug Therapy (Chemotherapy) 01/2017
1	Investigational Therapies (Experimental Therapy) 01/2017